Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- Check5 days agoChange DetectedThe ClinicalTrials.gov record for the afatinib–pembrolizumab lung cancer study is displayed with study details, eligibility criteria, outcome measures, locations, publications, and study documents.SummaryDifference56%

- Check12 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide NIH notice about terminology during the agency transition appears above the ClinicalTrials.gov page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record and blocking access to the trial details.SummaryDifference18%

- Check61 days agoChange DetectedThe page now displays Revision: v3.7.0 instead of v3.6.6, indicating an update to the site's interface version. This change relates to UI/versioning and does not alter the study details or content.SummaryDifference0.1%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.